ClinicalTrials.gg
CompletedNCT01428661MAGELLANUpdated Jun 19, 2015Results posted

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

A Phase 2/3 interventional study of tasimelteon and placebo in Major Depressive Disorder, sponsored by Vanda Pharmaceuticals. Completed at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-19.

Sponsored by Vanda Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
139th of 1,323
507 · median 70
Started
2011
with 83 others
Phase 2/3
22 of 1,500
none open now
Registered
510th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 139th largest by enrollment of the 1,323 interventional ones that give a count, is one of 84 that started in 2011, is one of 22 in phase 2/3, and was the 510th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.

Read the detailed description

This is a randomized, parallel, double-masked, placebo-controlled, multicenter outpatient study comparing tasimelteon with placebo in the treatment of subjects with Major Depressive Disorder (MDD).

The study has three phases: the pre-randomization phase, the randomization phase, and an open-label extension phase. The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated. The randomization phase is comprised of an 8-week double-masked segment. Subjects meeting all entry criteria for the study will enter the randomization phase. During this phase, subjects will be asked to take either 20 mg tasimelteon or placebo for 8 weeks in a double-masked fashion. At the end of the 8-week double-masked phase, those subjects who completed the 8-week treatment phase will be offered to enroll into a 52-week open-label extension where each subject will receive daily doses of 20 mg tasimelteon.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • tasimelteon
  • Major Depressive Disorder
  • MDD
  • depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with diagnosis of MDD, single or recurrent episode, according to TR criteria;
  • Current episode ≥4 weeks and ≤1 year;
  • CGI-Severity score ≥4 at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder;
  • Any other current Axis I (except general anxiety disorder as long as it is not considered the primary disorder) or Axis II disorder;
  • A positive test for drugs of abuse at the screening visit and/or history of drug or alcohol abuse/dependence as defined in TR, Diagnostic Criteria for Drug and Alcohol Abuse and Dependence, within the past 12 months;
  • Formal psychotherapy within 3 months of the screening visit. General supportive psychotherapy is acceptable;
  • Participation in a previous tasimelteon trial. Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    tasimelteon

    Drug: tasimelteon

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)

    Hamilton Rating Scale for Depression (HAM-D) assesses the range of symptoms that are most frequently observed in subjects with major depressive disorder (MDD) on a scale from 0 to 52. Higher HAM-D scores indicate more severe levels of depressive symptoms, thus, a negative change from baseline indicates a reduction (or improvement) in depressive symptoms.

    Time frame: 8 weeks

07

Results

Posted Jun 19, 2015

Participant flow

Double-Masked Phase
Participant flow — Double-Masked Phase
MilestoneTasimelteonPlaceboOpen Label Tasimelteon
Started2542530
Completed1972040
Not completed57490
Withdrew: Protocol violation940
Withdrew: Adverse event1340
Withdrew: Lost to follow-up14140
Withdrew: Withdrawal by subject18200
Withdrew: Lack of efficacy210
Withdrew: *various160
Open Label Extension
Participant flow — Open Label Extension
MilestoneTasimelteonPlaceboOpen Label Tasimelteon
Started00339
Completed0019
Not completed00320
Withdrew: Protocol violation009
Withdrew: Adverse event0015
Withdrew: Lost to follow-up0038
Withdrew: Withdrawal by subject0049
Withdrew: Lack of efficacy0024
Withdrew: **various00185

Outcome measures

PrimaryChange From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)

Hamilton Rating Scale for Depression (HAM-D) assesses the range of symptoms that are most frequently observed in subjects with major depressive disorder (MDD) on a scale from 0 to 52. Higher HAM-D scores indicate more severe levels of depressive symptoms, thus, a negative change from baseline indicates a reduction (or improvement) in depressive symptoms.

Time frame:
8 weeks
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)
units on a scaleTasimelteonPlaceboOpen Label Tasimelteon
Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)-8.19 ± 0.45-7.83 ± 0.45-13.6 ± 0.34

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tasimelteon—2/254 (0.8%)38/254 (15%)
Placebo—3/252 (1.2%)53/252 (21%)
Open Label Tasimelteon—6/339 (1.8%)74/339 (21.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventTasimelteonPlaceboOpen Label Tasimelteon
Chest PainGeneral disorders0/2540/2522/339
Non-Cardiac Chest PainGeneral disorders0/2541/2520/339
Blood Pressure IncreasedInvestigations0/2541/2520/339
Suicidal IdeationPsychiatric disorders0/2541/2520/339
Back PainMusculoskeletal and connective tissue disorders1/2540/2520/339
Suicide AttemptPsychiatric disorders1/2540/2520/339
CellulitisInfections and infestations0/2540/2521/339
Staphylococcal InfectionInfections and infestations0/2540/2521/339
Hepatitis AInfections and infestations0/2540/2521/339
Hepatitis BInfections and infestations0/2540/2521/339
Most frequent other events
Most frequent other events
EventTasimelteonPlaceboOpen Label Tasimelteon
HeadacheNervous system disorders29/25424/25234/339
NasopharyngitisInfections and infestations9/25412/25227/339
SomnolenceNervous system disorders17/25416/25210/339
Upper Respitory Tract InfectionInfections and infestations9/25415/25222/339
DiarrhoeaGastrointestinal disorders15/25413/2528/339
Dry MouthGastrointestinal disorders14/25410/2527/339

Baseline characteristics

Age, Continuous
Age, Continuous(years)TasimelteonPlaceboOpen Label TasimelteonTotal
Mean43.7 ± 12.6142.0 ± 12.46NA ± NA42.9 ± 12.54
Age, Continuous
Age, Continuous(years)TasimelteonPlaceboOpen Label TasimelteonTotal
MeanNA ± NANA ± NA44.1 ± 12.1944.1 ± 12.19
Gender
Gender(participants)TasimelteonPlaceboOpen Label TasimelteonTotal
Female1611710332
Male93820175
Gender
Gender(participants)TasimelteonPlaceboOpen Label TasimelteonTotal
Female00222222
Male00117117
08

Study locations

40 sites
  • Vanda Investigational Site
    Garden Grove, California 92845, United States
  • Vanda Investigational Site
    Irvine, California 92617, United States
  • Vanda Investigational Site
    Los Alamitos, California 90720, United States
  • Vanda Investigational Site
    Oakland, California 94612, United States
  • Vanda Investigational Site
    Oceanside, California 92056, United States
  • Vanda Investigational Site
    San Diego, California 92102, United States
  • Vanda Investigational Site
    Sherman Oaks, California 91403, United States
  • Vanda Investigational Site
    Torrance, California 90502, United States
  • Vanda Investigational Site
    Denver, Colorado 80239, United States
  • Vanda Investigational Site
    Bradenton, Florida 34201, United States
  • Vanda Investigational Site
    Jacksonville, Florida 32216, United States
  • Vanda Investigational Site
    Maitland, Florida 32751, United States
  • Vanda Investigational Site
    N. Miami, Florida 33161, United States
  • Vanda Investigational Site
    Orlando, Florida 32806, United States
  • Vanda Investigational Site
    Atlanta, Georgia 30308, United States
  • Vanda Investigational Site
    Atlanta, Georgia 30328, United States
  • Vanda Investigational Site
    Chicago, Illinois 60640, United States
  • Vanda Investigational Site
    Joliet, Illinois 60435, United States
  • Vanda Investigational Site
    Prairie Village, Kansas 66205, United States
  • Vanda Investigational Site
    Baltimore, Maryland 21208, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02135, United States
  • Vanda Investigational Site
    Omaha, Nebraska 68198, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89102, United States
  • Vanda Investigational Site
    Toms River, New Jersey 08755, United States
  • Vanda Investigational Site
    Willingboro, New Jersey 08046, United States
  • Vanda Investigational Site
    Brooklyn, New York 11235, United States
  • Vanda Investigational Site
    Mt. Kisco, New York 10549, United States
  • Vanda Investigational Site
    New York, New York 10168, United States
  • Vanda Investigational Site
    Rochester, New York 14618, United States
  • Vanda Investigational Site
    Staten Island, New York 10312, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45267, United States
  • Vanda Investigational Site
    Dayton, Ohio 45417, United States
  • Vanda Investigational Site
    Portland, Oregon 97210, United States
  • Vanda Investigational Site
    Lincoln, Rhode Island 02865, United States
  • Vanda Investigational Site
    Memphis, Tennessee 38119, United States
  • Vanda Investigational Site
    Austin, Texas 78731, United States
  • Vanda Investigational Site
    Dallas, Texas 75231, United States
  • Vanda Investigational Site
    Salt Lake City, Utah 84106, United States
  • Vanda Investigational Site
    Seattle, Washington 98104, United States
  • Vanda Investigational Site
    Brown Deer, Wisconsin 53223, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jan 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 2 years 5 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Sep 5, 2011
Start
Sep 2011
Primary completionActual
Jan 2013
CompletionActual
May 2013
Results delay requested
Jun 12, 2013
Results first posted
Jun 19, 2015
Last update
Jun 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01428661
Responsible party
Sponsor
First posted
Sep 5, 2011
Start date
Sep 2011
Primary completion
Jan 2013
Completion
May 2013
Results posted
Jun 19, 2015
Last update
Jun 19, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion